Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

AMD Clips|Criteria|PHGKB

AMD Clips Data Selection Criteria

Goal: identify articles describing the development or application of next-generation sequencing or other novel technologies to public health efforts to detect, monitor, prevent and control infectious diseases.

Include:

  • Novel methods for detecting or characterizing human pathogens, including laboratory techniques and analysis pipelines, bioinformatics tools, new reference databases.
  • Pathogen characterization, including genomic correlates of virulence and antimicrobial resistance; also, pathogen genotype-human phenotype correlation, e.g., disease severity or progression.
  • Pathogen genomic variation and evolution, including population surveys, comparative genomics, and within-host evolution; also, identification of novel pathogens and genome sequences.
  • Novel diagnostic techniques and tests; genomic correlates of classical phenotypes, e.g., serotype; use of genomic tests for surveillance.
  • Epidemiologic studies that incorporate genomic information to investigate disease transmission or outbreaks.
  • Novel antimicrobials and vaccines based on pathogen genomics; evaluation of public health interventions using pathogen or vector genomic markers, e.g., insecticide resistance.
  • Analyses of human microbiome; clinical or epidemiologic studies of host genetics in infectious diseases; human or pathogen genetics in relation to infectious causes of chronic diseases, e.g., hepatitis and liver cancer.

Exclude:

  • Classic microbiological methods, including serology and routine PCR; methods and resources for human genomics.
  • Environmental microbes or plant pathogens; phylogenetic studies based on single/few genes; Genome Announcements (unless CDC-authored).
  • Basic microbiological science, e.g., gene function; studies based on well-established molecular markers, e.g., for antimicrobial resistance.
  • Evaluation of commercial diagnostic tests.
  • Surveys of well-established molecular markers in clinical populations.
  • In vitro or animal studies of potential drugs or vaccines.
  • Studies focused on biomarkers of immunity.


General selection priorities:

  • Novel methods and applications - vs. – routine use of accepted methods.
  • Systematic, comprehensive, or unique studies – vs. – small, ad hoc, or routine clinical studies.
  • Public health relevance – vs. – specific to clinical practice.
  • CDC-sponsored or –authored.

  • Page last reviewed:Feb 1, 2024
  • Page last updated:Oct 31, 2024
TOP